Ticker reaction data
Allogene Therapeutics, Inc. (ALLO)
How ALLO actually reacts to news — the realized, point-in-time move the market made, measured across 313 labeled events over the last three years with zero look-ahead.
The quantified answer
ALLO’s median reaction, across the day.
+0.31%
Median 30-min
Typical reaction 30 minutes after any ALLO news
53%
Moved up
Share of ALLO news events that rose at 30 minutes
-0.54%
Median to close
Where ALLO typically settles by the closing bell
Median move vs. the price at the news timestamp, across 313 labeled events.
Next time, know first
Email me when ALLO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALLO’s baseline. Nothing else.
Prefer a one-pager?
Get “How ALLO reacts to news” as a PDF.
A free one-page summary: ALLO’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Latest news
Recent ALLO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update | Press release | GlobeNewswire | +0.80% | +1.60% | |
| Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma | Press release | GlobeNewswire | -0.87% | +5.23% | |
| Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors | Press release | GlobeNewswire | -2.41% | +1.60% | |
| Form 8-K Allogene Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.22% | +1.97% | |
| Allogene Therapeutics Announces Planned CEO Succession | Press release | GlobeNewswire | -4.40% | +0.46% | |
| Form 8-K Allogene Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -4.40% | +0.46% | |
| Form DEFA14A Allogene Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -4.40% | +0.46% | |
| Allogene Therapeutics Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.74% | +4.43% | |
| Form DEFA14A Allogene Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.64% | +4.25% | |
| Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | +0.00% | -6.96% | |
| Form 10-Q Allogene Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -6.96% | |
| Form 8-K Allogene Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.96% | |
| Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update | Press release | GlobeNewswire | -0.89% | +3.13% | |
| Form ARS Allogene Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.87% | +2.87% | |
| Form DEF 14A Allogene Therapeutics, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +1.87% | +2.87% | |
| Form DEFA14A Allogene Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.87% | +2.87% | |
| Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia | Press release | GlobeNewswire | -3.51% | -4.13% | |
| Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 | Press release | GlobeNewswire | +2.53% | +2.11% | |
| Form PRE 14A Allogene Therapeutics, For: Apr 20 | SEC filing · Form PRE | SEC EDGAR | -3.51% | -4.13% | |
| Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock | Press release | GlobeNewswire | +0.83% | -0.42% | |
| Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases | Press release | GlobeNewswire | +0.00% | +15.43% | |
| Form 8-K Allogene Therapeutics, For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +6.47% | +5.80% | |
| Allogene Therapeutics Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | +0.00% | +15.43% | |
| Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock | Press release | GlobeNewswire | -9.90% | -24.75% | |
| Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL | Press release | GlobeNewswire | -1.96% | -25.18% | |
| Form 8-K Allogene Therapeutics, For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | -1.96% | -25.18% | |
| Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 | Press release | GlobeNewswire | -1.96% | -25.18% | |
| Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update | Press release | GlobeNewswire | +2.93% | -6.25% | |
| Form 10-K Allogene Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.93% | -6.25% | |
| Form 8-K Allogene Therapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +2.93% | -6.25% | |
| Form S-8 Allogene Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +2.93% | -6.25% | |
| Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update | Press release | GlobeNewswire | -1.42% | +0.76% | |
| Allogene Therapeutics Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.39% | -9.44% | |
| Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T | Press release | GlobeNewswire | +1.01% | +0.68% | |
| Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis | Press release | GlobeNewswire | +0.00% | +1.99% | |
| Allogene Therapeutics Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.03% | -4.07% | |
| Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update | Press release | GlobeNewswire | +3.77% | +12.38% | |
| Form 10-Q Allogene Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.77% | +12.38% | |
| Form 8-K Allogene Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +3.77% | +12.38% | |
| Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting | Press release | GlobeNewswire | -0.40% | -5.60% | |
| Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update | Press release | GlobeNewswire | +2.48% | +0.00% | |
| Form 8-K Allogene Therapeutics, For: Sep 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Allogene Therapeutics Announces Participation in Upcoming Investor Conference | Press release | GlobeNewswire | +3.48% | +0.87% | |
| Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update | Press release | GlobeNewswire | +1.94% | +1.91% | |
| Form 10-Q Allogene Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.94% | +1.91% | |
| Form 8-K Allogene Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | +1.91% | |
| Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update | Press release | GlobeNewswire | +0.00% | -3.64% | |
| Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma | Press release | GlobeNewswire | +1.25% | -10.00% | |
| Form 8-K Allogene Therapeutics, For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | +1.25% | -10.00% | |
| Form 8-K Allogene Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | +2.46% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALLO section they belong to.
Keep exploring
More of the dataset.
ALLO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.